Supplementary Figure S3 from Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma

Change from baseline PD-L1 expression. Data included are for patients with matched fresh tumor biopsies at baseline and cycle 2, day 8 (C2D8) of nivolumab treatment. Each solid line represents a patient. The horizontal dotted line represents 5% PD-L1 expression.